Lupin Limited has informed the Exchange regarding a press release dated February 10, 2025, titled "Lupin Receives Approval from U.S. FDA for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03%".
Lupin Limited has informed the Exchange regarding a press release dated February 10, 2025, titled "Lupin Receives Approval from U.S. FDA for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03%".